Wael Fayad

Mr. Fayad is a Managing Partner at Hildred Capital Management, where he currently serves on the Board of Directors of three Hildred portfolio companies: Project Natural, Carlin Consumer Health, and Crown Laboratories. Mr. Fayad previously served in an operating role at Hildred Capital Partners, closely involved with certain Hildred portfolio companies, leveraging his depth of experience to enhance strategic positioning, operational efficiency and overall growth trajectory, most notably as Chief Business Officer of Crown Laboratories.

Prior to Hildred, Mr. Fayad spent more than 25 years in pharma and biotech where he started his career in sales, marketing, and new products at Novartis and then Schering-Plough. He worked at Forest Laboratories Inc. for 14 years and served as Corporate Vice President of Business Development. After leaving Forest, he advised and worked with biotech and start-up life sciences companies including co-founding Accoy Pharmaceuticals and serving as Chairman and CEO of Enumeral Biomedical.

Through his personal and professional experience, Mr. Fayad developed a deep appreciation for authenticity to build long term value. Outside of work, he enjoys the outdoors, reading, and spending time with friends and family. He holds a Bachelor of Science in Biology from the American University of Beirut and an MBA from Concordia University.